Taysha Gene Therapies (NASDAQ:TSHA) PT Lowered to $34.00 at Chardan Capital

Taysha Gene Therapies (NASDAQ:TSHA – Get Rating) had its price target dropped by analysts at Chardan Capital from $37.00 to $34.00 in a note issued to investors on Tuesday, The Fly reports.

Several other research analysts have also recently issued reports on TSHA. Needham & Company LLC cut their price objective on Taysha Gene Therapies to $20.00 and set a “buy” rating for the company in a research report on Tuesday. Wells Fargo & Company started coverage on Taysha Gene Therapies in a report on Tuesday, March 1st. They issued an “overweight” rating and a $25.00 target price on the stock. Zacks Investment Research lowered Taysha Gene Therapies from a “buy” rating to a “hold” rating in a report on Wednesday, April 6th. Guggenheim lowered their target price on Taysha Gene Therapies to $22.00 and set a “na” rating on the stock in a report on Tuesday. Finally, The Goldman Sachs Group lowered their target price on Taysha Gene Therapies from $34.00 to $27.00 and set a “buy” rating on the stock in a report on Friday, April 1st. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, Taysha Gene Therapies currently has an average rating of “Buy” and an average target price of $29.64.

NASDAQ:TSHA traded down $0.07 during trading hours on Tuesday, hitting $3.25. The company’s stock had a trading volume of 6,062 shares, compared to its average volume of 255,917. The business’s 50-day moving average is $5.29 and its two-hundred day moving average is $8.90. The company has a market capitalization of $131.53 million, a PE ratio of -0.70 and a beta of 2.23. The company has a debt-to-equity ratio of 0.39, a quick ratio of 3.08 and a current ratio of 3.08. Taysha Gene Therapies has a 52-week low of $2.69 and a 52-week high of $26.99.

Taysha Gene Therapies (NASDAQ:TSHA – Get Rating) last released its quarterly earnings data on Monday, May 16th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by ($0.28). During the same period in the previous year, the firm posted ($0.87) earnings per share. As a group, analysts predict that Taysha Gene Therapies will post -3.73 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of TSHA. Renaissance Technologies LLC purchased a new position in Taysha Gene Therapies during the first quarter worth about $1,633,000. JPMorgan Chase & Co. lifted its position in Taysha Gene Therapies by 85.1% during the first quarter. JPMorgan Chase & Co. now owns 439,804 shares of the company’s stock worth $2,868,000 after buying an additional 202,245 shares during the period. Vanguard Group Inc. lifted its position in Taysha Gene Therapies by 14.5% during the first quarter. Vanguard Group Inc. now owns 1,012,164 shares of the company’s stock worth $6,599,000 after buying an additional 128,517 shares during the period. State Street Corp lifted its position in Taysha Gene Therapies by 31.8% during the fourth quarter. State Street Corp now owns 464,169 shares of the company’s stock worth $5,408,000 after buying an additional 111,983 shares during the period. Finally, Geode Capital Management LLC lifted its position in Taysha Gene Therapies by 37.8% during the third quarter. Geode Capital Management LLC now owns 363,016 shares of the company’s stock worth $6,759,000 after buying an additional 99,574 shares during the period. 46.05% of the stock is currently owned by institutional investors and hedge funds.

About Taysha Gene Therapies (Get Rating)

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.

Read More